Comparison Between Tramadol Hcl and Other Analgesics in the Treatment of Renal Colic
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether Tramadol Hcl is as effective as Voltaren a non-steroidal antiinflammatory drug, and Dipyrone in amelioration of the pain caused by acute renal colic.
| Condition | Intervention | Phase |
|---|---|---|
|
Renal Calculus |
Drug: Tramadol Hcl |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Efficacy of Tramadol Hcl in the Treatment of Renal Colic |
- Pain improvement according to VAS score at 30, 60 and 120 minutes(Stage I) [ Time Frame: 30, 60, 120 minutes ] [ Designated as safety issue: No ]
- Need for rescue medication at 30 minutes (Stage I) [ Time Frame: 30 minutes ] [ Designated as safety issue: Yes ]
- Pain improvement according to VAS score at 24 and 48 hrs (Stage II) [ Time Frame: 24 and 48 hrs ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 100 |
| Study Start Date: | September 2006 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
-
Drug: Tramadol Hcl
Renal stones is a common condition affecting up to 1% of the american population. The main symptom is renal colic. Acute treatment is based on the administration of analgesics mainly those belonging to non-steroidal antiinflammatory drugs (NSAIDs). Tramadol is an analgesic of the opioid class of analgesics (i.e morphine) and it is considered to cause less side effects with more or less the same analgesic potency. In the present study the analgesic effect of intramuscular Tramadol will be compared with Voltaren (NSAID)in patients attending the Emergency Department (ED) for acute renal colic (Stage I). Most of these patients will not pass their stone during their visit to the ED and they are prone to develop another attack of renal colic.In the second phase of the study (Stage II)patients who improved, and are ready to go home, will be enrolled to get Dipyrone or Tramadol orally for the prevention of further pain.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with clinical diagnosis of acute renal colic (Stage I)
- Patients with diagnosed renal colic who might need prevention of pain and are able to swallow medicines (Stage II)
Exclusion Criteria:
- Patients with known hypersensitivity to the study drugs
- Pregnancy or lactation
- Known renal failure or hepatic disease
- Concommitant drug use which could adversely affect patient's outcome (oral anticoagulant, MAO inhibitors)
Contacts and Locations| Israel | |
| Hadassah Medical Organization | |
| Jerusalem, Israel, 12000 | |
| Principal Investigator: | Ruth Stalnikowicz, MD | Hadassah Medical Organization |
More Information
Publications:
| Responsible Party: | Ruth Stalnikowicz, Hadassah Medical Organization |
| ClinicalTrials.gov Identifier: | NCT00310908 History of Changes |
| Other Study ID Numbers: | 1234567-HMO-CTIL |
| Study First Received: | April 4, 2006 |
| Last Updated: | February 15, 2009 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Hadassah Medical Organization:
|
Renal Colic Calculi Treatment |
Additional relevant MeSH terms:
|
Calculi Kidney Calculi Renal Colic Pathological Conditions, Anatomical Nephrolithiasis Kidney Diseases Urologic Diseases Urolithiasis Urinary Calculi Colic Abdominal Pain Pain Signs and Symptoms |
Signs and Symptoms, Digestive Tramadol Narcotics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Analgesics, Opioid |
ClinicalTrials.gov processed this record on May 23, 2013